VivoSeq
Other

Interaction

0

Pipeline Programs↗

40

Active Trials↗

157

Companies Involved↗

Interaction is an early-stage landscape with 0 programs across 157 companies. The most active players are GSK, Pfizer, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

52/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAstellas logo

Astellas

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

1,102

clinical trials

Completed980 · 89%
Unknown status44 · 4%
Not yet recruiting25 · 2%
Terminated24 · 2%
Withdrawn14 · 1%
Recruiting11 · 1%
Other4 · 0%

Clinical Trials

Trial Activity

1102 trials

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Recruiting·HHyundai Pharm·Phase 1·NCT06578676·56 enrolled
Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints
Recruiting·WWashington State University·Phase 1·NCT05846451·16 enrolled
Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers
Recruiting·RRobin Carhart-Harris, PhD, MA·Phase 2·NCT06626139·120 enrolled
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants
Recruiting·Jiangsu Simcere Pharmaceutical Co., Ltd. logoJiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT07357610·60 enrolled
A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants
Recruiting·IInstitut de Recherches Internationales Servier (I.R.I.S.)·Phase 1·NCT07235774·28 enrolled
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
Recruiting·Incyte logoIncyte·Phase 1·NCT06909162·51 enrolled
A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers
Recruiting·KKorea United Pharm. Inc.·Phase 1·NCT07162441·50 enrolled
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Recruiting·IIndiana University·Phase 1·NCT05789173·60 enrolled
Interaction of Volatile Anesthetics With Magnesium
Recruiting·—·Phase 4·NCT05261516·96 enrolled
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
Recruiting·National Institute on Drug Abuse (NIDA)·Phase 1·NCT05143424·60 enrolled
Opioid Drug Interaction Study
Recruiting·—·Phase 1/2·NCT06757140·25 enrolled
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
Active, not recruiting·AAligos Therapeutics·Phase 1·NCT06672900·24 enrolled
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
Active, not recruiting·VVincentage Pharma Co., Ltd·Phase 1·NCT07065058·24 enrolled
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
Active, not recruiting·HHuons Co., Ltd.·Phase 1·NCT06618079·46 enrolled
Drug-Drug Interaction Study in Trans Women Living With HIV
Active, not recruiting·MMaple Leaf Research·Phase 4·NCT05663892·45 enrolled
Page 1 of 74

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)